标题
The Biology and Targeting of FLT3 in Pediatric Leukemia
作者
关键词
-
出版物
Frontiers in Oncology
Volume 4, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2014-09-23
DOI
10.3389/fonc.2014.00263
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
- (2014) W. Zhang et al. CLINICAL CANCER RESEARCH
- Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival
- (2014) Y. Kikushige et al. JOURNAL OF IMMUNOLOGY
- Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia
- (2013) Michael J. Burke et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
- (2013) A. Galanis et al. BLOOD
- MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism
- (2013) Edward Allan R. Sison et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia
- (2013) S. D. Baker et al. CLINICAL CANCER RESEARCH
- NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease
- (2013) Rachel Rau et al. EXPERIMENTAL HEMATOLOGY
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
- (2013) Michael R. Grunwald et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
- (2013) C Albers et al. LEUKEMIA
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
- (2013) Kerstin Maria Kampa-Schittenhelm et al. Molecular Cancer
- FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice
- (2013) E. Bailey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model
- (2012) S. Greenblatt et al. BLOOD
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm
- (2012) S. Haihua Chu et al. Cell Stem Cell
- A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
- (2012) B. C. Widemann et al. CLINICAL CANCER RESEARCH
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
- (2012) Stephen P. Hunger et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
- (2012) A B Williams et al. LEUKEMIA
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model
- (2012) K Reckzeh et al. LEUKEMIA
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia
- (2012) M C Chillón et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group
- (2012) Matthew A. Kutny et al. PEDIATRIC BLOOD & CANCER
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
- (2011) Amy E. DeZern et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib
- (2011) Manish Sharma et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice
- (2011) L. Li et al. BLOOD
- Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation
- (2011) S. Kharazi et al. BLOOD
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
- (2011) A. Parmar et al. CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia
- (2011) Hiroto Inaba et al. JOURNAL OF CLINICAL ONCOLOGY
- Favorable Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Children With High-risk or Advanced Acute Myeloid Leukemia
- (2011) Kyung Nam Koh et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Challenging issues in pediatric oncology
- (2011) Ching-Hon Pui et al. Nature Reviews Clinical Oncology
- Further activation of FLT3 mutants by FLT3 ligand
- (2011) R Zheng et al. ONCOGENE
- Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia
- (2011) Tanya C. Watt et al. PEDIATRIC BLOOD & CANCER
- Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells
- (2010) Friedrich Stölzel et al. ANNALS OF HEMATOLOGY
- Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies
- (2010) C. O'Keefe et al. BLOOD
- Genomic analysis of acute myeloid leukemia: potential for new prognostic indicators
- (2010) Elizabeth A Eklund CURRENT OPINION IN HEMATOLOGY
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
- (2010) N von Bubnoff et al. LEUKEMIA
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
- (2010) Michael Crump et al. LEUKEMIA & LYMPHOMA
- Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report
- (2010) J. Winkler et al. LEUKEMIA RESEARCH
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
- (2009) S. Kayser et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
- (2009) S. Metzelder et al. BLOOD
- Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
- (2009) J. Zhou et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression
- (2009) Hiroki Yamaguchi et al. EXPERIMENTAL HEMATOLOGY
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2009) Kirk R. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor
- (2008) F. Breitenbuecher et al. BLOOD
- Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
- (2008) L. Li et al. BLOOD
- Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
- (2008) M. Raghavan et al. BLOOD
- Whole genome scanning as a cytogenetic tool in hematologic malignancies
- (2008) J. P. Maciejewski et al. BLOOD
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
- (2008) K. W. Pratz et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
- (2008) B. Nervi et al. BLOOD
- A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects
- (2008) Ophelia Q P Yin et al. CLINICAL PHARMACOKINETICS
- Childhood Acute Myeloid Leukemia
- (2008) Jeffrey E. Rubnitz CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment
- (2008) U Mony et al. LEUKEMIA
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now